Romagné et al., 2011 - Google Patents
Natural killer cell-based therapiesRomagné et al., 2011
View HTML- Document ID
- 1004231435826429459
- Author
- Romagné F
- Vivier E
- Publication year
- Publication venue
- F1000 medicine reports
External Links
Snippet
Allotransplantation of natural killer (NK) cells has been shown to be a key factor in the control and cure of at least some hematologic diseases, such as acute myeloid leukemia or pediatric acute lymphocytic leukemia. These results support the idea that stimulation of NK …
- 210000000822 Killer Cells, Natural 0 title abstract description 114
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wolf et al. | Novel approaches to exploiting invariant NKT cells in cancer immunotherapy | |
Romagné et al. | Natural killer cell-based therapies | |
Giganti et al. | Treg cell therapy: How cell heterogeneity can make the difference | |
Bachanova et al. | NK cells in therapy of cancer | |
Szmania et al. | Ex vivo–expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients | |
Wiebking et al. | Genome editing of donor-derived T cells to generate allogeneic chimeric antigen receptor-modified T cells: optimizing αβ T-cell-depleted haploidentical hematopoietic stem cell transplantation | |
Davies et al. | Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease | |
Spel et al. | Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma | |
Heinrichs et al. | Regulatory T-cell therapy for graft-versus-host disease | |
Locatelli et al. | At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies | |
Scheper et al. | Cancer immunotherapy using γδT cells: dealing with diversity | |
Kannan et al. | Natural killer cells in malignant hematology: A primer for the non-immunologist | |
CN106661129A (en) | Chimeric antigen receptor specific for SSEA4 antigen | |
Torelli et al. | A good manufacturing practice method to ex vivo expand natural killer cells for clinical use | |
Norell et al. | At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias | |
Besser et al. | Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies | |
Moretta et al. | Human NK receptors: from the molecules to the therapy of high risk leukemias | |
Ghio et al. | Down regulation of human natural killer cell–mediated cytolysis induced by blood transfusion: role of transforming growth factor‐β1, soluble Fas ligand, and soluble Class I human leukocyte antigen | |
Biernacki et al. | T cell optimization for graft-versus-leukemia responses | |
Hont et al. | The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease | |
WO2016185476A1 (en) | Methods of obtaining mononuclear blood cells and uses thereof | |
Pierini et al. | NK cell and CD4+ FoxP3+ regulatory T cell based therapies for hematopoietic stem cell engraftment | |
Schmid et al. | Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells | |
Zhang et al. | Imm TAC/Anti‐PD‐1 antibody combination to enhance killing of cancer cells by reversing regulatory T‐cell‐mediated immunosuppression | |
Duan et al. | Targeting NK cells for HIV-1 treatment and reservoir clearance |